TY - JOUR
T1 - Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases
AU - Drop, B. R. H.
AU - Zemel, D.
AU - Wokke, B. H. A.
AU - van Oosten, B. W.
AU - Dik, S.
AU - Martins Jarnalo, C. O.
AU - Westerweel, P. E.
AU - de Beukelaar, J. W. K.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Alemtuzumab is effective in relapsing remitting multiple sclerosis (RRMS). Serious adverse events have led to a renewed safety reassessment by the European Medicines Agency (EMA), leading to an approval under strict conditions. We report a RRMS patient experiencing diffuse alveolar hemorrhage (DAH) on day 4 of her first alemtuzumab cycle. In addition, we present an overview of the cases of alemtuzumab-induced DAH that were included in EMA's review procedure, additional well documented cases reported to the EMA and those cases reported in the literature. Combining these cases revealed striking similarities. Importantly, DAH was an early complication. All RRMS patients with known outcome showed complete recovery.
AB - Alemtuzumab is effective in relapsing remitting multiple sclerosis (RRMS). Serious adverse events have led to a renewed safety reassessment by the European Medicines Agency (EMA), leading to an approval under strict conditions. We report a RRMS patient experiencing diffuse alveolar hemorrhage (DAH) on day 4 of her first alemtuzumab cycle. In addition, we present an overview of the cases of alemtuzumab-induced DAH that were included in EMA's review procedure, additional well documented cases reported to the EMA and those cases reported in the literature. Combining these cases revealed striking similarities. Importantly, DAH was an early complication. All RRMS patients with known outcome showed complete recovery.
KW - Adverse events
KW - Alemtuzumab
KW - Diffuse alveolar hemorrhage
KW - Hemoptysis
KW - Multiple sclerosis
KW - Respiratory symptoms
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85096851735&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/33249378
U2 - 10.1016/j.msard.2020.102614
DO - 10.1016/j.msard.2020.102614
M3 - Comment/Letter to the editor
C2 - 33249378
VL - 47
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
M1 - 102614
ER -